Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 2.1
5-Year Impact Factor – 2.2
Scopus CiteScore – 3.4 (CiteScore Tracker 3.4)
Index Copernicus  – 161.11; MEiN – 140 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2017, vol. 26, nr 1, January-February, p. 177–182

doi: 10.17219/acem/27319

Publication type: review article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Bethesda System in the evaluation of thyroid nodules: Review

Marta Wesoła1,A,B,C,D, Michał Jeleń1,E,F

1 Department of Pathomorphology and Oncological Cytology, Wroclaw Medical University, Poland

Abstract

Fine needle aspiration (FNA) biopsy is an important and widely accepted method used in the diagnosis of patients with thyroid nodules.The lack of consistency in reporting FNA taken from the thyroid gland has led to divergences in the calculation of the sensitivity and specificity of the method. Discrepancies depend on what was considered to be true or false negative/positive. This resulted in confusion among doctors, who had to decide how to manage the patient with constantly changing positive or negative results of the FNA. The problem was solved in 2007, when “The Bethesda System for Reporting Thyroid Cytopathology” (TBSRTC) was introduced. Generally, TBSRTC, compared to previous systems, results in reducing the number of non-diagnostic/indeterminate cases and enables a better clinical usefulness of the results of the FNA of the thyroid gland. This is probably due to the introduction of more standard criteria for interpreting and reporting. TBSRTC improves communication between cytopathologists, reduces the number of unnecessary operations on benign lesions, and makes it possible to perform the operation on time in patients with malignant lesions and predict the risk of thyroid cancer. It provides a simple and reliable exchange of data not only between various laboratories but also between institutions throughout the world. Research shows that all indicators of malignancy calculated for all categories have similar value to the recommended rate of malignancy.

Key words

thyroid, Bethesda System, cytology, fine-needle aspiration, terminology

References (40)

  1. Sakorafas GH. Thyroid nodules; interpretation and importance of fineneedle aspiration (FNA) for the clinician – practical considerations. Surg Oncol. 2010;19(4):130–139.
  2. Yoder BJ, Redman R, Massoll NA. Validation of a five-tier cytodiagnostic system for thyroid fine needle aspiration biopsies using cytohisto-logic correlation. Thyroid. 2006;16(8):781–786.
  3. Cibas ES, Ali SZ. NCI thyroid FNA state of the science conference the Bethesda System For Reporting Thyroid Cytopathology. Am J Clin Pathol. 2009;132(5):658–665.
  4. Layfield LJ, Cibas ES, Baloch Z. Thyroid fine needle aspiration cytology: A review of the National Cancer Institute state of the science sympo-sium. Cytopathology. 2010;21(2):75–85.
  5. Nayar R, Ivanovic M. The indeterminate thyroid fine-needle aspiration: Experience from an academic center using terminology similar to that proposed in the 2007 National Cancer Institute Thyroid Fine Needle Aspiration State of the Science Conference. Cancer. 2009;117(3):195–202.
  6. Cibas ES, Ali SZ. The Bethesda System for Reporting Thyroid Cytopathology. Am J Clin Pathol. 2009;132:658–665.
  7. Auger M, Nayar R, Khalbuss WE, et al. Implementation of the Bethesda System for Reporting Thyroid Cytopathology: Observations from the 2011 Thyroid Supplemental Questionnaire of the College of American Pathologists. Arch Pathol Lab Med. 2013;10(137):1555–1559.
  8. De Silva C. The Bethesda System for Reporting Thyroid Cytopathology: Should Sri Lanka adopt it? Ceylon J Otolaryngol. 2013;3(1):9–14.
  9. Seneviratne B. Interpretation of fine needle aspiration cytology of thyroid: Do we need a better classification? Sri Lanka J Diabetes, Endo-crinol Metab. 2012;2:32–34.
  10. Baloch ZW, Alexander EK, Gharib H, Raab SS. Chapter 1. In: Ali SZ, Cibas ES, eds. The Bethesda System for Reporting Thyroid Cytopathology. New York, NY: Springer;2010:1–4.
  11. VanderLaan PA, Renshaw AA, Krane JF. Atypia of undetermined significance and nondiagnostic rates in the Bethesda System for Reporting Thyroid Cytopathology are inversely related. Am J Clin Pathol. 2012;137:462–465.
  12. Renshaw AA. Non-diagnostic rates for thyroid fine needle aspiration are negatively correlated with positive for malignancy rates. Acta Cytol. 2011;55:38–41.
  13. Krane JF, VanderLaan PA, Faquin WC, Renshaw AA. The atypia of undetermined significance/follicular lesion of undetermined significance. Malignant ratio: A proposed performance measure for reporting in the Bethesda System for thyroid cytopathology. Cancer Cytopathol. 2012;120(2):111–116.
  14. Pathak P, Srivastava R, Singh N, Arora VK, Bhatia A. Implementation of the Bethesda System for Reporting Thyroid Cytopathology: Interob-server concordance and reclassification of previously inconclusive aspirates (published online on April 1 2014). Diagn Cytopathol. 2014. doi: 10.1002/dc.23162.
  15. Song JY, Chu YC, Kim L, Park IS, Han JY, Kim JM. Reclassifying formerly indeterminate thyroid FNAs using the Bethesda system reduces the number of inconclusive cases. Acta Cytol. 2012;56(2):122–129.
  16. Richmond BK, O’Brien BA, Mangano W, Thompson S, Kemper S. The Impact of implementation of the Bethesda System for Reporting Thyroid Cytopathology on the surgical treatment of thyroid nodules. Am Surg. 2012;78(6):706–710.
  17. Kiernan CM, Broome JT, Solórzano CC. The Bethesda System for Reporting Thyroid Cytopathology: A single-center experience over 5 years [published online on May 6 2014]. Ann Surg Oncol. 2014. doi: 10.1245/s10434-014-3743-1.
  18. McElroy MK, Mahooti S, Hasteh F. A single institution experience with the new Bethesda System for Reporting Thyroid Cytopathology: Correlation with existing cytologic, clinical, and histological data [published online on January 16 2014]. Diagn Cytopathol. 2014. doi: 10.1002/dc.2307.
  19. Rabaglia JL, Kabbani W, Wallace L, et al. Effect of the Bethesda system for reporting thyroid cytopathology on thyroidectomy rates and ma-lignancy risk in cytologically indeterminate lesions. Surgery. 2010;148(6):1267–1272.
  20. Bongiovanni M, Spitale A, Faquin WC, Mazzucchelli L, Baloch ZW. The Bethesda System for Reporting Thyroid Cytopathology: A meta-analysis. Acta Cytol. 2012;56:333–339.
  21. Hershman JM. The Bethesda System for Reporting Thyroid Cytopathology is effective for clinical management of thyroid nodules. Clin Thy-roidol. 2013;25:16–17.
  22. Crowe A, Linder A, Hameed O, et al. The impact of implementation of the Bethesda System for Reporting Thyroid Cytopathology on the quality of reporting, ‘‘risk’’ of malignancy, surgical rate, and rate of frozen sections requested for thyroid lesions. Cancer. Cancer Cytopathol. 2011;119:315–321.
  23. Olson MT, Boonyaarunnate T, Atlinboga AA, Ali SZ. ‘Suspicious for papillary thyroid carcinoma’ before and after The Bethesda System for Reporting Thyroid Cytopathology: Impact of standardized terminology. Acta Cytol. 2014;58:15–22.
  24. Olson MT, Boonyaarunnate T, Han PA, Umbricht CB, Ali SZ. A tertiary center’s experience with second review of 3885 thyroid cytopathology specimens. J Clin Endocrinol Metab. 2013;98(4):1450–1457.
  25. Prabath IHDS, Priyani AAH, Lokuhetty MDS. Diagnostic terminology for reporting thyroid cytology: Inter-observer agreement between the format currently used in Sri Lanka and the Bethesda system. J Diagn Pathol. 2013;8(2):13–22.
  26. Jing X, Knoepp SM, Roh MH, et al. Group consensus review minimizes the diagnosis of “follicular lesion of undetermined significance” and improves cytohistologic concordance. Diagn Cytopathol. 2012;40(12):1037–1042.
  27. Mufti ST, Molah R. The Bethesda System for Reporting Thyroid Cytopathology: A five-year retrospective review of one center experience. Int J Health Sci. 2012;6(2):131–143.
  28. Lee K, Jung CK, Lee KY. Application of Bethesda System for Reporting Thyroid Aspiration Cytology. Korean J Pathol. 2010;44(5): 521–527.
  29. Jo VY, Stelow EB, Dustin SM, Hanley KZ. Malignancy risk for fine-needle aspiration of thyroid lesions according to the Bethesda System for Reporting Thyroid Cytopathology. Am J Clin Pathol. 2010;134:450–456.
  30. Wu HH, Rose C, Elsheikh TM. The Bethesda System for Reporting Thyroid Cytopathology: An experience of 1,382 cases in a community prac-tice setting with the implication for risk of neoplasm and risk of malignancy. Diagn Cytopathol. 2012:40(5);399–403.
  31. Yassa L, Cibas ES, Benson CB, et al. Long-term assessment of a multidisciplinary approach to thyroid nodule diagnostic evaluation. Cancer. 2007;6:508–516.
  32. Yang J, Schnadig V, Logrono R, et al. Fine-needle aspiration of thyroid nodules: A study of 4703 patients with histologic and clinical correla-tions. Cancer. 2007;5:306–315.
  33. Mondal SK, Sinha S, Basak B, Roy DN, Sinha SK. The Bethesda System for reporting thyroid fine needle aspirates: A cytologic study with histo-logic follow-up. J Cytol. 2013;30(2):94–99.
  34. Tepeoğlu M, Bilezikçi B, Bayraktar SG. A histological assessment of the Bethesda System for Reporting Thyroid Cytopathology (2010) abnor-mal categories: A series of 219 consecutive cases. Cytopathology. 2014;25(1):39–44.
  35. Sheffield BS, Masoudi H, Walker B, Wiseman SM. Preoperative diagnosis of thyroid nodules using the Bethesda System for Reporting Thyroid Cytopathology: A comprehensive review and meta-analysis. Expert Rev Endocrinol Metab. 2014;9(2);97–110.
  36. Ohori NP, Schoedel KE. Variability in the atypia of undetermined significance/follicular lesion of undetermined significance diagnosis in the Bethesda System for Reporting Thyroid Cytopathology: Sources and recommendations. Acta Cytol. 2011;55(6):92–98.
  37. Broome JT, Solorzano CC. The impact of atypia/follicular lesion of undetermined significance on the rate of malignancy in thyroid fi-ne-needle aspiration: Evaluation of the Bethesda System for Reporting Thyroid Cytopathology. Surgery. 2011;150(6):1234–1241.
  38. Layfield LJ, Morton MJ, Cramer HM, Hirschowitz S. Implications of the proposed thyroid fine-needle aspiration category of “follicular lesion of undetermined significance”: A five-year multi-institutional analysis. Diagn Cytopathol. 2009;10:710–714.
  39. Singh RS, Wang HH. Eliminating the “atypia of undetermined significance/follicular lesion of undetermined significance” category from the Bethesda System for Reporting Thyroid Cytopathology. Am J Clin Pathol. 2011;136:896–902.
  40. Walts AE, Mirocha J, Bose S. Follicular lesion of undetermined significance in thyroid fna revisited. Diagn Cytopathol. 2014;42(1):18–22.
© Wroclaw Medical University